GRAIL aims to detect cancer early when it can be cured. Diagnosing cancer early results in significantly higher survival rates compared to late-stage diagnosis. Using the power of high-intensity sequencing, population-scale clinical trials, and state of the art computer science and data science GRAIL aims to enhance the scientific understanding of cancer biology. The company develops blood tests and blood screens for early-stage cancer detection.